Curriculum Vitaes

tokoro takamasa

  (所 隆昌)

Profile Information

Affiliation
School of Medicine, Faculty of Medicine, Fujita Health University
Degree
博士(医学)

J-GLOBAL ID
201501014672385188
researchmap Member ID
7000012873

Misc.

 12
  • 棚橋義直, 杉岡 篤, 加藤悠太郎, 所 隆昌, 新田隆士, 香川 幹, 竹浦千夏, 宇山一朗
    日本門脈圧亢進症学会雑誌, 19(4) 200-204, Nov, 2013  
  • 所 隆昌, 加藤悠太郎, 香川 幹, 棚橋義直, 新田隆士, 杉岡 篤
    INNERVISION, 28(6) 92-93, May, 2013  
  • 杉岡 篤, 加藤悠太郎, 所 隆昌, 棚橋義直, 須田康一, 宇山一朗
    手術, 66(12) 1681-1688, 2012  
  • 竹浦千夏, 杉岡 篤, 加藤悠太郎, 所 隆昌, 棚橋義直, 香川 幹, 新田隆士, 伊藤泰平, 黒澤良和
    藤田医学会誌, 36(1) 131-138, 2012  
  • Keiichi Suzuki, Zenichi Morise, Shinpei Furuta, Yoshinao Tanahashi, Chinatsu Takeura, Tadashi Kagawa, Masahiro Ikeda, Atsushi Sugioka
    Case Reports in Gastroenterology, 5(1) 152-158, Jan, 2011  
    Sarcoidosis is a multisystemic granulomatous disease of unknown etiology. Hepatic involvement was reported in about 11% of patients with sarcoidosis. However, cases of sarcoidosis in which the granuloma is solitary and limited in the liver are very rare. A 51-year-old woman with tumors in the liver underwent extended left lobectomy with caudate lobectomy and bile duct resection. The tumor was located between segment 4 and the hilar region. Some daughter nodules were found in the left lobe, which were regarded as intrahepatic metastasis. Our case displayed clinical and radiologically distinct findings, which are very similar to those of hilar cholangiocarcinoma restricted to the liver. This report demonstrates that sarcoidosis can show solitary hepatic involvement in the absence of thoracic lymphadenopathy. In such a case, it is difficult to distinguish the diagnosis from other malignant neoplasms. In conclusion, the diagnosis of hepatic sarcoidosis has to be made through prudent and comprehensive investigations that include a full clinical history of sarcoidosis in other organs. Despite utilizing several detailed diagnostic modalities, the definitive diagnosis of cases of solitary sarcoidosis may remain difficult. In these cases, surgical treatment including liver resection should be considered in order to avoid missing a suitable opportunity for treatment. © 2011 S. Karger AG, Basel.
  • 池田匡宏, 守瀬 善一, 竹浦千夏, 香川 幹, 棚橋義直, 岡部安博, 所 隆昌, 溝口良順, 杉岡 篤
    日本消化器外科学会雑誌, 43(11), 2010  
  • 所 隆昌, 杉岡 篤, 棚橋義直, 竹浦千夏, 香川 幹, 岡部安博, 守瀬善一, 高桑康成, 黒田 誠
    胆道, 24(5) 700-706, 2010  
  • 守瀬善一, 杉岡 篤, 所 隆昌, 棚橋義直, 岡部安博, 香川 幹, 竹浦千夏
    消化器内科, 50(1) 86-91, 2010  
  • Zenichi Morise, Atsushi Sugioka, Takamasa Tokoro, Yoshinao Tanahashi, Yasuhiro Okabe, Tadashi Kagawa, Chinatsu Takeura
    World Journal of Hepatology, 2(2) 58-64, 2010  
    Cholangiocarcinoma, arising from bile duct epithelium, is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), including hilarcholangiocarcinoma. Recently, there has been a worldwide increase in the incidence and mortality from ICC. Complete surgical resection is the only approach to cure the patients with ICC. However, locoregional extension of these tumors is usually advanced with intrahepatic and lymph-node metastases at the time of diagnosis. Resectability rates are quite low and variable (18%-70%). The five-year survival rate after surgical resection was reported to be 20%-40%. Median survival time after ICC resection was 12-37.4 mo. Only a small number of ICC cases, accompanied with ECC, gall bladder carcinoma, and ampullary carcinoma, have been reported in the studies of chemotherapy due to the rarity of the disease. However, in some reports, significant anti-cancer effects were achieved with a response rate of up to 40% and a median survival of one year. Although recurrence rate after hepatectomy is high for the patients with ICC, the residual liver and the lung are the main sites of recurrence after tentative curative surgical resection. Several patients in our study had a long-term survival with repeated surgery and chemotherapy. Repeated surgery, combined with new effective regimens of chemotherapy, could benefit the survival of ICC patients. © 2010 Baishideng.
  • Zenichi Morise, Atsushi Sugioka, Yoshinao Tanahashi, Yasuhiro Okabe, Masahiro Ikeda, Tadashi Kagawa, Chinatsu Takeura
    ANTICANCER RESEARCH, 29(5) 1783-1786, May, 2009  
    Background: The results of 12 consecutive patients with unresectable advanced biliary tract carcinoma treated with first line chemotherapy of S1/cisplatin, combined surgical resection and second line chemotherapy of gemcitabine are evaluated. Patients and Methods: Eight patients with intrahepatic cholangiocarcinoma, 1 with extrahepatic cholangiocarcinoma and 3 with gallbladder carcinoma were included in the study. All patients were treated with S1/cisplatin. Two of the patients underwent combined surgical resection before and 2 after therapy. Second line chemotherapy of gemcitabine was administerd in 6 patients. Results: MST of the patients was 14.9 months. With S1/cisplatin therapy, 6 patients had PR and 4 had SD. Two patients with surgical resection after the therapy survived more than 3 years. Second line chemotherapy of gemcitabine with moderate effects and mild adverse effects was well tolerable. Conclusion: S1/cisplatin showed considerable anti-cancerous effects. Employing surgical resection for patients with good response may lead to the chance of long-term survival.
  • 高田英輝, 佐藤榮作, 所 隆昌, 折原明, 松永研吾
    日本臨床外科学会雑誌, 68(1) 86-90, 2007  
  • 所 隆昌, 金子哲也, 岡田菜緒, 高田英輝, 佐藤榮作, 折原明
    外科, 69(4) 428-486, 2007